AstraZeneca and Hutchmed Initiate P-III SANOVO Trial for Orpathys (savolitinib) + Tagrisso (osimertinib) as a 1L Therapy for Non-small Cell Lung Cancer in China

September 9, 2021 Auto Bot AstraZeneca, China, Clinical Trials, Hutchmed, Non-Small Cell Lung Cancer, osimertinib, P-III, Tagrisso 0

Shots:

  • The companies initiate P-III SANOVO study to evaluates the efficacy & safety of Orpathys in combination with AstraZeneca’s Tagrisso (irreversible EGFR TKI) vs Tagrisso alone in patients with NSCLC whose tumors harbor EGFR mutation and overexpress MET. The first patient was dosed on Sept 7, 2021
  • The 1EPs of the study is m-PFS as assessed by investigators & other EPs include m-PFS as assessed by IRC, m-OS, ORR, DoR, DCR, time to response, and safety
  • In 2011, the companies collaborated to jointly develop & commercialize savolitinib where Hutchmed will lead marketing authorization, manufacturing & supply of the therapy in China & AstraZeneca is responsible for the commercialization globally

Click here to read full press release/ article | Ref: Globe Newswire | Image: Pharmaletter

The post AstraZeneca and Hutchmed Initiate P-III SANOVO Trial for Orpathys (savolitinib) + Tagrisso (osimertinib) as a 1L Therapy for Non-small Cell Lung Cancer in China first appeared on PharmaShots.